GLP-1/GIP treatment at Choose Healthy

At Choose Healthy, Dr. Gina Casian focuses on optimizing patients' cardiometabolic health, with the goal of reversing and preventing chronic conditions such as type 2 diabetes, obesity, and cardiovascular disease. She has led a physician-supervised weight-loss clinic for over one year, where she prescribes FDA-approved GLP-1 and dual GLP-1/GIP receptor agonists. She possesses extensive expertise in current clinical guidelines, evidence-based use criteria, and best practices for these therapies.

GLP-1/GIP Receptor Agonists at Choose Healthy

• FDA-approved highly effective anti-obesity medications, in accordance with the latest clinical guidelines and established medical criteria. When patients meet eligibility requirements, these prescriptions are typically covered by insurance.

• Compounded formulations for overweight patients or patients with obesity who do not yet qualify for branded medications

• All treatment plans incorporate close monitoring of dosing and potential side effects with an initial comprehensive laboratory evaluation to rule out contraindications. Patients receive personalized guidance to support sustained adherence to evidence-based intensive lifestyle modifications.

• Dr. Casian prescribes compounded formulations through reputable and experienced pharmacies with PCAB Accreditation and 503B Outsourcing Facilities to ensure quality and efficacy standards.

• At Choose Healthy, we prioritize transparent and patient-centered pricing for medications. We do not apply markups, premiums, or additional fees to the costs negotiated directly with our highly trusted, preferred pharmacy.

Understanding the Differences Between FDA-Approved GLP-1/GIP Therapies and Compounded Medications

GLP-1 and GIP therapies have transformed the treatment landscape for type 2 diabetes and obesity. These medications help regulate blood sugar and support weight loss by mimicking natural hormones that control appetite and insulin release. As their popularity grows, patients and healthcare providers face a choice between FDA-approved brand medications and compounded alternatives. Understanding the differences between these options is essential for making informed decisions about safety, effectiveness, and cost.

The 2026 clinical guidelines from the ADA, ACC, and WHO prioritize GLP-1 and GIP agonists as foundational therapies for chronic weight management and cardiovascular protection.

​Key Serious Complications

​Most hospitalizations are driven by severe gastrointestinal or metabolic events:

• ​Acute Pancreatitis: A serious risk that has led to updated safety warnings and, in rare cases, can be fatal.

• ​Gastrointestinal Distress: Severe vomiting or diarrhea can cause acute kidney injury due to dehydration.

• ​Intestinal Obstruction: Some large-scale database analyses show a higher risk of obstruction requiring hospitalization compared to other diabetes medications.

• ​Compounded Formulations: Hospitalization odds are roughly 2.35 times higher for compounded products due to dosing or preparation errors.

Key Clinical Trials

• ​SELECT (Semaglutide): Found that 2.4 mg of semaglutide reduced the risk of major adverse cardiovascular events (MACE)—including heart attack, stroke, and cardiovascular death—by 20% in adults with overweight or obesity and established heart disease, even without diabetes.

• ​SURPASS-CVOT (Tirzepatide): Published in early 2026, this head-to-head trial confirmed that the dual GLP-1/GIP agonist tirzepatide is non-inferior to dulaglutide for reducing MACE. It also showed significant reductions in all-cause mortality and secondary composite endpoints including heart failure events.

• ​FLOW (Semaglutide): Demonstrated that semaglutide significantly reduces the risk of major kidney disease events and cardiovascular mortality in patients with type 2 diabetes and chronic kidney disease.

Synergy with Lifestyle: Recent Harvard studies (2026) highlight that while these drugs are highly effective, their benefits are substantially amplified when combined with healthy lifestyle habits, reducing MACE risk by up to 43%.

The STEP 1 extension trial, published in Diabetes, Obesity and Metabolism in 2022. Researchers followed participants for 52 weeks after they stopped taking 2.4 mg of semaglutide and found that they regained two-thirds of their prior weight loss on average. The data also showed that the cardiometabolic improvements seen during the treatment phase largely returned to baseline levels within that year.

Why Choose FDA-Approved Medications?

• Proven safety and efficacy through large clinical trials

• Consistent manufacturing standards ensuring purity and dosage accuracy

• Clear dosing guidelines and monitoring recommendations

• Insurance coverage often available, reducing out-of-pocket costs

• Regulatory oversight that protects patients from harmful or ineffective products

  
  
  
  

Compounded GLP-1/GIP Medications: Benefits and Risks

Compounded medications are custom-made by pharmacists to meet specific patient needs. They may combine ingredients or adjust doses not available in commercial products. Some patients turn to compounded GLP-1 or GIP therapies when they cannot access FDA-approved options or seek lower-cost alternatives. Compounded drugs are not FDA-approved. They are legally permitted primarily when a patient has a specific medical need that cannot be met by an approved drug (e.g., an allergy to a dye) or during an official FDA drug shortage.

Potential Benefits of Compounded Medications

• Customized dosing tailored to individual patient requirements

• Potential cost savings when insurance does not cover brand medications

• Access in areas with limited availability of FDA-approved drugs

  
  

Risks and Limitations of Compounded GLP-1/GIP Therapies

• Safety Warning: The FDA recently issued warnings against "mass-marketed" compounded versions and "salt forms" of these drugs, noting they cannot verify their safety or bio-equivalence to the brand-name versions

• Variable quality and potency due to less stringent manufacturing controls

• Increased risk of contamination or incorrect dosing

• Limited clinical data supporting their use in diabetes or weight management

• Insurance typically does not cover compounded medications, leading to higher out-of-pocket costs

• Potential legal and regulatory issues depending on state laws and pharmacy practices

  
  

Important Considerations

Patients should discuss compounded medication options thoroughly with their healthcare providers. Pharmacists compounding these drugs must follow strict guidelines, but the absence of FDA oversight means patients bear more risk. Compounded therapies may be appropriate in rare cases but require careful monitoring.

Practical Advice for Patients

• Ask about FDA approval when considering GLP-1 or GIP therapies. Approved medications have known safety profiles.

• Understand the risks of compounded medications and ensure they come from reputable pharmacies with experience in compounding formulations.

• Monitor treatment closely if using compounded therapies, reporting any side effects or concerns immediately.

• Quality Control: If prescribing compounded products, ensure the pharmacy is a state-licensed 503A or 503B facility and verify that they use high-quality, non-salt base APIs from the FDA "green list.

  
  

GLP-1 and GIP therapies offer powerful tools for managing diabetes and obesity. Choosing between FDA-approved medications and compounded alternatives involves weighing safety, effectiveness, cost, and availability. FDA-approved drugs provide proven benefits with regulatory oversight, while compounded medications offer customization but carry more risks.